日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Joint modeling of progression-free survival and patient-reported outcomes to evaluate the association between disease progression and symptoms among patients with relapsed/refractory multiple myeloma

联合构建无进展生存期和患者报告结局模型，以评估复发/难治性多发性骨髓瘤患者疾病进展与症状之间的关联

期刊:Journal of Patient-Reported Outcomes
影响因子:2.9
doi:10.1186/s41687-025-00943-9
Knop, Stefan; Einsele, Hermann; Dhanda, Devender; Marshall, Thomas S; Eliason, Laurie; McLoone, Dylan; Caisip, Clyde; Chen, Jenny M H; Boehm, Doris; Dhamane, Amol D; Ramasamy, Karthik; Cope, Shannon; Towle, Kevin
多发性骨髓瘤
骨髓瘤
发表日期：2025
文献求助 收藏

A scoping review of visual communication of written patient health information preferences including a Māori perspective

一项关于书面患者健康信息偏好视觉传达的范围界定综述，包括毛利人的视角

期刊:Health Education Research
影响因子:2
doi:10.1093/her/cyaf005
Caisip, A; Kremer, L; Edmonds, L; Young, A
发表日期：2025
文献求助 收藏

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer

间接比较鲁比替定与其他二线治疗方案在小细胞肺癌治疗中的疗效

期刊:Journal of Comparative Effectiveness Research
影响因子:2.5
doi:10.57264/cer-2022-0098
Hanvesakul, Raj; Rengarajan, Badri; Naveh, Navit; Boccuti, Anne; Park, Julie E; Adeyemi, Adekemi; Caisip, Clyde; Jansen, Jeroen P; Wilson, Florence R
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏

P1740: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IDECABTAGENE VICLEUCEL VS BELANTAMAB MAFODOTIN: A MATCHING-ADJUSTED INDIRECT COMPARISON STUDY

P1740：接受 idecabatagene vicleucel 治疗的复发/难治性多发性骨髓瘤 (RRMM) 患者的健康相关生活质量与接受 belantamab mafodotin 治疗的患者的比较：一项匹配调整的间接比较研究

期刊:Hemasphere
影响因子:14.6
doi:10.1097/HS9.0000000000000783
Schutgens, Roger E G; Shah, N; Ayers, D; Cope, S; Karampampa, K; Towle, K; Braverman, J; Mojebi, A; Caisip, C; Dhanda, D
多发性骨髓瘤
骨髓瘤
发表日期：2022
文献求助 收藏